Does Cory Anderson have any related-party or family relationships with Neuronetics (STIM) leadership?

The company states there is no arrangement or understanding with any other person regarding his selection, and no family relationships with directors or other executive officers. It also reports no related‑party transactions requiring disclosure under Item 404(a) of Regulation S‑K.

Neuronetics promotes Cory Anderson to EVP role

Neuronetics, Inc. announced that its board of directors has promoted Cory Anderson to Executive Vice President, General Manager of Greenbrook, effective July 1, 2026.

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

8-K

Rhea-AI Filing Summary

Neuronetics, Inc. announced that its board of directors has promoted Cory Anderson to Executive Vice President, General Manager of Greenbrook, effective July 1, 2026. He moves from his prior role as Senior Vice President, Chief Technology Officer and brings over 25 years of medical device leadership experience.

In connection with the promotion, Anderson’s annual base salary will increase to $425,000, and his target discretionary annual cash bonus will be set at 45% of his then-current base salary. He will remain eligible for annual equity grants under the company’s long‑term incentive program and continues under existing indemnification, restrictive covenant, and severance agreements.

8-K Event Classification

2 items: 5.02, 9.01

2 items

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

Key Figures

Base salary: $425,000 per year Target bonus: 45% of base salary Promotion effective date: July 1, 2026 +2 more

5 metrics

Base salary $425,000 per year Effective July 1, 2026 for EVP, GM of Greenbrook role

Target bonus 45% of base salary Target discretionary annual cash bonus after promotion

Promotion effective date July 1, 2026 Anderson Promotion Date to EVP, GM of Greenbrook

Anderson age 49 years Age of newly promoted Executive Vice President

Experience Over 25 years Medical device industry and executive leadership experience

Key Terms

Executive Vice President, General Manager of Greenbrook, long-term incentive program, executive indemnification agreement, restrictive covenant and severance agreement

4 terms

Executive Vice President, General Manager of Greenbrook financial

"promoted Cory Anderson from the position of Senior Vice President, Chief Technology Officer to the position of Executive Vice President, General Manager of Greenbrook"

long-term incentive program financial

"Mr. Anderson will continue to be eligible to receive annual equity grants under the Company’s long-term incentive program"

A long-term incentive program is a company plan that pays executives or employees rewards—often stock, options, or cash—only if the business hits performance goals over several years. It matters to investors because these payouts align managers’ interests with shareholders, encouraging decisions that boost sustained growth and share value rather than short-term gains; think of it as a multi-year bonus tied to measurable company outcomes.

executive indemnification agreement financial

"Mr. Anderson had previously entered into the Company’s executive indemnification agreement"

restrictive covenant and severance agreement financial

"executive restrictive covenant and severance agreement, and restrictive covenant and invention assignment agreement"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What executive leadership change did Neuronetics (STIM) disclose on June 16, 2026?

Neuronetics disclosed that its board promoted Cory Anderson to Executive Vice President, General Manager of Greenbrook, effective July 1, 2026. He previously served as Senior Vice President, Chief Technology Officer, following multiple prior R&D and clinical leadership roles within the company.

How is Cory Anderson’s compensation changing with his new role at Neuronetics (STIM)?

Effective July 1, 2026, Cory Anderson’s annual base salary will increase to $425,000. His target discretionary annual cash bonus will also rise, set at 45% of his then‑current base salary, while he remains eligible for annual equity grants under the long‑term incentive program.

What is Cory Anderson’s professional background before his promotion at Neuronetics (STIM)?

Cory Anderson has over 25 years of medical device experience, including roles at Sebacia, The Innovation Factory, Accuitive Medical Ventures, and Novoste Corporation. He has managed clinical trials, R&D pipelines, business development, marketing, and operations for multiple venture‑backed and ophthalmic portfolio companies.

What prior positions has Cory Anderson held within Neuronetics (STIM)?

Within Neuronetics, Anderson served as SVP R&D and Clinical, Chief Technology Officer since January 2025, SVP R&D and Clinical before that, VP R&D and Clinical, and VP Clinical Affairs and Medical Operations, Interim VP R&D, reflecting a steady progression through senior technical and clinical leadership roles.

Will Cory Anderson continue to receive equity-based incentives at Neuronetics (STIM)?

Yes. The filing notes that, as before his promotion, Cory Anderson will remain eligible to receive annual equity grants under Neuronetics’ long‑term incentive program. He is also party to the company’s standard executive indemnification, restrictive covenant, severance, and invention assignment agreements.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 06/23/2026 - 04:38 PM EDT

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) June 16, 2026

NEURONETICS, INC.

(Exact name of registrant as specified in its charter)

Delaware

001-38546

33-1051425

(State or other jurisdiction
of incorporation)

(Commission

File Number)

(I.R.S. Employer
Identification No.)


3222 Phoenixville Pike, Malvern, PA		19355
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code (877) 600-7555

(Former name or former address, if changed since last report.) Not applicable.

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol (s)	Name on each exchange on which registered
Common Stock ($0.01 par value)	STIM	The Nasdaq Global Market

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(c) On June 16, 2026, the board of directors of the Company (the “Board”) promoted Cory Anderson from the position of Senior Vice President, Chief Technology Officer to the position of Executive Vice President, General Manager of Greenbrook effective July 1, 2026 (the “Anderson Promotion Date”).

There is no arrangement or understanding between Mr. Anderson and any other person pursuant to which he was selected as an officer of the Company, and there is no family relationship between Mr. Anderson and any of the Company’s directors or other executive officers. There are no related party transactions between Mr. Anderson and the Company that would require disclosure under Item 404(a) of Regulation S-K.

Mr. Anderson, age 49, has over 25 years of experience along with deep executive leadership within medical device companies. Mr. Anderson previously served as the Company’s SVP R&D and Clinical, Chief Technology Officer since January 2025, SVP R&D and Clinical from January 2023 until December 2024, VP R&D and Clinical from January 2022 until December 2022 and VP Clinical Affairs and Medical Operations, Interim VP R&D from March 2021 until December 2021. Prior to joining the Company, Mr. Anderson served as Vice President, Business Development and Marketing at Sebacia. During his time at Sebacia, he led phase IV clinical trials in five countries and strategically guided the company’s R&D pipeline. Prior to Sebacia, he was VP Business Development at The Innovation Factory (“TIF”) and a Principal at Accuitive Medical Ventures (“AMV”). During his time at TIF and AMV, Mr. Anderson managed operations of two portfolio companies in the ophthalmic space, evaluated new business and investment opportunities, and supported investments in the portfolio of companies. Prior to his time at TIF and AMV, Mr. Anderson held positions of increasing responsibility within Product Development and Marketing at Novoste Corporation where he developed products for interventional cardiology. Mr. Anderson has been a board observer and investor in two successful exits of venture-backed companies: AqueSys (acquired by Allergan/AbbVie, NYSE: ABBV) and MyoScience (acquired by Pacira BioSciences, NASDAQ: PCRX). Mr. Anderson holds Bachelor’s and Master’s degrees in Biomedical Engineering from Tulane University, and an MBA from Emory University. Mr. Anderson is an inventor on seven issued US patents and an author of two peer-reviewed papers and one book chapter.

In connection with Mr. Anderson’s promotion, the Board has approved changes to Mr. Anderson’s employment terms. Effective as of the Anderson Promotion Date, Mr. Anderson’s annual base salary will be increased to $425,000, and Mr. Anderson’s target discretionary annual cash bonus will be increased to 45% of his then-current base salary. As was the case prior to the Anderson Promotion Date, Mr. Anderson will continue to be eligible to receive annual equity grants under the Company’s long-term incentive program.

Mr. Anderson had previously entered into the Company’s executive indemnification agreement, executive restrictive covenant and severance agreement, and restrictive covenant and invention assignment agreement, each substantially in the form of the Company’s applicable template agreement.

Item 9.01

Financial Statements and Exhibits.

(d) Exhibits.


Exhibit Number		Description

104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


	NEURONETICS, INC.
	(Registrant)

Date: June 23, 2026	By:	/s/ W. Andrew Macan
	Name:	W. Andrew Macan
	Title:	Executive Vice President, Chief Legal Officer, and Corporate Secretary

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

3 documents